Crossmark

Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database

Crossref DOI link: https://doi.org/10.1186/s40780-026-00565-3

Published Online: 2026-03-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Takatsu, Nao

Matsumoto, Jun

Oka, Yurie

Sakai, Tomonori

Iwata, Naohiro

Higashionna, Tsukasa

Takeda, Tatsuaki

Hamano, Hirofumi

Zamami, Yoshito
License Information

Text and Data Mining valid from 2026-03-27

Version of Record valid from 2026-05-07
More Information

Article History

Received: 27 January 2026

Accepted: 23 March 2026

First Online: 27 March 2026

Declarations

:

: The requirement for ethics approval and informed consent was waived, as this observational study used fully anonymised patient data.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below